WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib. WZ4002 has a basic chemical framework (covalent pyrimidine) which is different from that of other EGFR inhibitors. This agent is 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wildtype EGFR, than quinazoline-based EGFR inhibitors (HKI-272 and CL-387,785) in vitro.
EGFR Inhibitors Related Products:
Erlotinib; Erlotinib hcl; Gefitinib; AG-490; Dacomitinib; Pelitinib; Brigatinib analog; Allitinib; Rociletinib; Varlitinib; Icotinib; WHI-P154; CNX-2006; AG-18; Nazartinib